440 related articles for article (PubMed ID: 20070992)
1. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
Younis F; Kariv N; Nachman R; Zangen S; Rosenthal T
Clin Exp Hypertens; 2007 Aug; 29(6):419-26. PubMed ID: 17729058
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal glucose homeostasis in Cohen-Rosenthal diabetic hypertensive rats.
Younis F; Oron Y; Limor R; Stern N; Rosenthal T
Metabolism; 2012 Feb; 61(2):164-74. PubMed ID: 21820685
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Rinaldi B; Di Filippo C; Capuano A; Donniacuo M; Sodano L; Ferraraccio F; Rossi F; D'Amico M
Diabetes Obes Metab; 2012 Apr; 14(4):320-8. PubMed ID: 22050607
[TBL] [Abstract][Full Text] [Related]
5. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
[TBL] [Abstract][Full Text] [Related]
6. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
Kamari Y; Harari A; Shaish A; Peleg E; Sharabi Y; Harats D; Grossman E
Hypertens Res; 2008 Jan; 31(1):135-40. PubMed ID: 18360028
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients.
Mori H; Okada Y; Arao T; Nishida K; Tanaka Y
Adv Ther; 2012 Jul; 29(7):635-44. PubMed ID: 22821644
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients.
Hong SJ; Choi SC; Ahn CM; Park JH; Kim JS; Lim DS
Heart; 2011 Sep; 97(17):1425-32. PubMed ID: 21700754
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients.
Chujo D; Yagi K; Asano A; Muramoto H; Sakai S; Ohnishi A; Shintaku-Kubota M; Mabuchi H; Yamagishi M; Kobayashi J
Hypertens Res; 2007 Dec; 30(12):1205-10. PubMed ID: 18344626
[TBL] [Abstract][Full Text] [Related]
16. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.
Negro R; Hassan H
J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):243-6. PubMed ID: 17318795
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Takai S; Jin D; Kimura M; Kirimura K; Sakonjo H; Tanaka K; Miyazaki M
Hypertens Res; 2007 Dec; 30(12):1231-7. PubMed ID: 18344629
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
